CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Fluoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02473250
NCT02473250Phase 4Completed
CompareCT.gov

Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

New York State Psychiatric Institute·interventional·Posted Jun 16, 2015·Updated Dec 31, 2024

In Brief

A Phase 4 clinical trial evaluating Fluoxetine and Citalopram for Bipolar Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study is for subjects with a diagnosis of bipolar disorder who have depression at the time of recruitment. It involves brain imaging with an MRI (magnetic resonance imaging) and PET scan (positron emission tomography) and treatment with an antidepressant. The medication involves adding an SSRI (either celexa/citalopram or prozac/fluoxetine) to a mood stabilizer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 16, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 11.0 years ago

Interventions

Fluoxetinedrug

Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).

Citalopramdrug

Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.